Exchange: MIL Sector: Healthcare Industry: Diagnostics & Research
-0.11% €92.02
America/New_York / 3 mai 2024 @ 11:35
FUNDAMENTALS | |
---|---|
MarketCap: | 4 910.19 mill |
EPS: | 2.87 |
P/E: | 32.06 |
Earnings Date: | May 10, 2024 |
SharesOutstanding: | 53.36 mill |
Avg Daily Volume: | 0.187 mill |
RATING 2024-05-03 |
---|
S |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Strong Buy | |
P/E: | Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
1.25x |
Company: PE 32.06 | sector: PE 25.67 |
PE RATIO: COMPANY / INDUSTRY |
---|
1.26x |
Company: PE 32.06 | industry: PE 25.36 |
DISCOUNTED CASH FLOW VALUE |
---|
€240.69 (161.57%) €148.67 |
Date: 2024-05-04 |
Expected Trading Range (DAY) |
---|
€ 89.55 - 94.50 ( +/- 2.69%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | €92.02 (-0.11% ) |
Volume | 0.0984 mill |
Avg. Vol. | 0.187 mill |
% of Avg. Vol | 52.53 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.